Market Intel: Pain Management I: Spinal-Cord Stim To Grab Ever-Bigger Market Share
Executive Summary
The field of neuromodulation for treating chronic pain is growing rapidly, especially in the fastest-growing spinal cord stimulation (SCS) market segment, which is expected to hit $2.4bn by 2021. This article, the first of a two-part series, will explore what the key drivers and limitations are for the SCS market and provide insight from three established pain management specialists on what factors will push wider adoption of this therapy.
You may also be interested in...
Market Intel: NANS 2018: Positive Data Intensifies Spinal-Cord Stim's Big-Four Rivalry
The market for spinal cord stimulation (SCS) systems, used for treating chronic debilitating pain, is expanding relentlessly, and companies like Abbott Laboratories, Medtronic, Boston Scientific and Nevro are all vying to gain more market share with their respective technologies. At this year's annual meeting of the North American Neuromodulation Society (NANS) in Las Vegas, physicians were presented with the latest clinical evidence backing these innovations. This article looks at the overall SCS market, discusses study findings presented at NANS and the latest innovations. It also provides insights from two established pain management specialists on factors they think will drive SCS technologies forward.
JPM2018: Nevro Announces FDA Nod For Next-Gen Senza II Device
Redwood City, Calif.-based device-maker Nevro Corp. kicked off the annual J.P. Morgan Healthcare Conference in San Francisco on Jan. 8 with the announcement it received US FDA approval for its next-generation Senza II spinal cord stimulation system and better-than-expected Q4 earnings results.
INS 2017 Aims To Offer Sneak Peek Into Future Neuromodulation Trends
As scientific and industry experts prepare to gather in Edinburgh, Scotland, later this month for the 13th International Neuromodulation Society Congress, Medtech Insight spoke to Timothy Deer, INS president and a pain-management specialist, about what's ahead in neuromodulation and what to expect at the meeting.